New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
IQIRVO® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baseline In the first real-world analysis in patients with PBC and an ALP 1-1.67 x ULN, IQIRVO demonstrated a significant ALP reduction, with 59% of patients achieving ALP normalization at 6 months Interim analysis from the ELFINITY Phase […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.